Consortium for Genomic Technologiessocieta Benefit SRL

Consortium for Genomic Technologiessocieta Benefit SRL is an SME in Milan, Italy that has taken part in 5 EU-funded projects since 2021, receiving €315k in EU funding.

EU funding received€315k
EU projects5
As coordinator0
Running now4
First EU project2021
Latest project2023
CountryItaly
EU registration (PIC)904616472
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Consortium for Genomic Technologiessocieta Benefit SRL's own share of each project, not the project's full budget.

  • Horizon Europe€259k · 3 projects
  • Horizon 2020€55k · 2 projects

Projects

5 EU-funded projects, newest first. Each links to the official record.

  • METABALANCANCERAssociated partner

    Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy

    Horizon Europe · 2023–2028 · Project on CORDIS ↗

  • SagittariusAssociated partner

    A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS - THE SAGITTARIUS TRIAL

    Horizon Europe · 2023–2028 · Project on CORDIS ↗

  • STRIKEPartner

    Comprehensive STRategIes to tacKlE malignant tumors: from nanomedicine and theranostics to precision medicine

    Horizon Europe · 2023–2026 · Project on CORDIS ↗

    €259ktheir share
  • TARGETAssociated partner

    Targeting DNA repair pathways, sparking anti cancer immunity

    Horizon 2020 · 2021–2027 · Project on CORDIS ↗

  • diaRNAgnosisPartner

    A novel platform for the direct profiling of circulating cell-free ribonucleic acids in biofluids

    Horizon 2020 · 2021–2025 · Project on CORDIS ↗

    €55ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • DNA
  • RNA
  • breast cancer
  • colorectal cancer
  • genetics
  • immunotherapy
  • mutation
  • nano-materials
  • nanomedicine
  • nanotechnology
  • nutrition
  • oncology
  • personalized medicine
  • proteins

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime